China's Biggest Hepatitis B Vaccine Maker Gains 2.1% in Sharp Swing on Hong Kong Debut

Shares of AIM Vaccine Co. Ltd., China’s second-largest vaccine maker, jumped 2.1% on its Hong Kong debut Thursday after a bumpy initial public offering.

The company raised a net HK$70.01 million ($9.84 million) of from selling 9.7 million shares at HK$16.16 per share. The stock opened at HK$15 per share and recovered over the day.

The vaccine maker joined a growing list of biopharmaceutical companies that have opted to go public with low issuance volumes in the face of a cooling IPO market and limited external financing.